Literature DB >> 10581085

Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes.

D E Michele1, F P Albayya, J M Metzger.   

Abstract

Familial hypertrophic cardiomyopathy is a clinically and genetically diverse autosomal dominant disorder characterized by ventricular hypertrophy and myocyte disarray in the absence of known hypertrophic stimuli. It has been linked to many cardiac contractile proteins, including four point mutations in alpha-tropomyosin (Tm). Here we use adenoviral-mediated gene transfer into adult cardiac myocytes in vitro to show that all four hypertrophic cardiomyopathy alpha-Tm proteins can be expressed and incorporated into normal sarcomeric structures in cardiac myocytes at similar levels as normal alpha-Tm proteins after 5-6 days in culture. Isometric force recordings of single cardiac myocytes demonstrated inappropriate increased force output at submaximal calcium concentration with a specific mutant allele hierarchy. These data indicate that the severity of direct calcium-sensitizing effect of mutations in alpha-Tm may predict the clinical severity of mutant alpha-Tm-associated hypertrophic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581085     DOI: 10.1038/70990

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  26 in total

Review 1.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

2.  Gene transfer into cardiac myocytes.

Authors:  Sarah E Lang; Margaret V Westfall
Journal:  Methods Mol Biol       Date:  2015

Review 3.  Nuclear tropomyosin and troponin in striated muscle: new roles in a new locale?

Authors:  P Bryant Chase; Mark P Szczypinski; Elliott P Soto
Journal:  J Muscle Res Cell Motil       Date:  2013-08-02       Impact factor: 2.698

Review 4.  Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes.

Authors:  Jil C Tardiff
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

5.  Enhanced active cross-bridges during diastole: molecular pathogenesis of tropomyosin's HCM mutations.

Authors:  Fan Bai; Adam Weis; Aya K Takeda; P Bryant Chase; Masataka Kawai
Journal:  Biophys J       Date:  2011-02-16       Impact factor: 4.033

Review 6.  Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.

Authors:  A J Marian; L Salek; S Lutucuta
Journal:  Minerva Med       Date:  2001-12       Impact factor: 4.806

7.  Combinatorial effects of double cardiomyopathy mutant alleles in rodent myocytes: a predictive cellular model of myofilament dysregulation in disease.

Authors:  Jennifer Davis; Joseph M Metzger
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

Review 8.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

9.  Myofilament lattice structure in presence of a skeletal myopathy-related tropomyosin mutation.

Authors:  Julien Ochala; Hiroyuki Iwamoto
Journal:  J Muscle Res Cell Motil       Date:  2013-05-18       Impact factor: 2.698

10.  Defective regulation of contractile function in muscle fibres carrying an E41K beta-tropomyosin mutation.

Authors:  Julien Ochala; Meishan Li; Monica Ohlsson; Anders Oldfors; Lars Larsson
Journal:  J Physiol       Date:  2008-04-17       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.